医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd & Zhangjiajie Tourism Group Co. Ltd Entered a Strategic Cooperation Agreement

2016年01月01日 AM08:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

As at January 1, 2016, Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd (“Zhangjiajie Jinchi”), a wholly-owned subsidiary of Jinchi Biotech Ltd ( “Jinchi Biotech”)(NSX:JCB), entered a strategic cooperation agreement (the “Strategic Cooperation Agreement”) with Zhangjiajie Tourism Group Co. Ltd (“Zhangjiajie Tourism Group”, stock code:000430).

Zhangjiajie Jinchi and Zhangjiajie Tourism Group will cooperate on marketing, promoting, advertising and training, and share advertisement resources and launch a new exquisite tourism route: Yangjiajie, Baofeng Lake and Zhangjiajie Giant Salamander Science Museum.

Zhangjiajie Tourism Group is a state-owned holding company listed on the Shenzhen Stock Exchange with tourism resources development, tourism infrastructure construction, high-tech development in tourism industry, and security investment consultancy services as its main business. In 2014, Zhangjiajie Tourism Group achieved annual operating income about AUD$ 104,350,000 (RMB 484,009,400) and received nearly 5 million tourists, among which Yangjiajie and Baofeng Lake attracted 339,300 and 562,400 tourists respectively.

The Strategic Cooperation Agreement, which is mainly focused on Zhangjiajie tourism industry, can help promote Zhangjiajie Giant Salamander Science Museum to worldwide tourists and enhance brand effect and advertising effect. This agreement is expected to bring Zhangjiajie Giant Salamander Science Museum more than 200,000 tourists, which may greatly increase ticket proceeds and product sales revenue in 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151231005058/en/

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続